TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I IFN Hyperactivation

Molecular Mechanism and Rationale

The molecular cascade underlying TBK1 loss-of-function-mediated synapse elimination involves a complex interplay between defective autophagy, cellular senescence, and complement-driven synaptic pruning. TBK1 (TANK-binding kinase 1) serves as a critical regulatory kinase that phosphorylates key autophagy receptors, including OPTN (optineurin) at Ser177 and p62/SQSTM1 at Ser403. These phosphorylation events are essential for the recruitment of LC3-II to autophagosomes and the subsequent clearance of ubiquitinated protein aggregates through selective autophagy. In ALS/FTD patient-derived neurons carrying TBK1 mutations (particularly those affecting the kinase domain such as G294V and E696K), this phosphorylation cascade is severely impaired, leading to accumulation of TDP-43, FUS, and SOD1 aggregates within neuronal cytoplasm.

Molecular Mechanism and Rationale

The molecular cascade underlying TBK1 loss-of-function-mediated synapse elimination involves a complex interplay between defective autophagy, cellular senescence, and complement-driven synaptic pruning. TBK1 (TANK-binding kinase 1) serves as a critical regulatory kinase that phosphorylates key autophagy receptors, including OPTN (optineurin) at Ser177 and p62/SQSTM1 at Ser403. These phosphorylation events are essential for the recruitment of LC3-II to autophagosomes and the subsequent clearance of ubiquitinated protein aggregates through selective autophagy. In ALS/FTD patient-derived neurons carrying TBK1 mutations (particularly those affecting the kinase domain such as G294V and E696K), this phosphorylation cascade is severely impaired, leading to accumulation of TDP-43, FUS, and SOD1 aggregates within neuronal cytoplasm.

The autophagy dysfunction triggers a cascade of cellular stress responses that culminate in senescence-like phenotypes. Accumulated protein aggregates activate the cGAS-STING pathway through cytosolic DNA release from damaged mitochondria, as TBK1 deficiency also impairs PINK1-Parkin-mediated mitophagy. This leads to sustained activation of IRF3 and IRF7 transcription factors, driving expression of type I interferons, particularly IFN-β. The senescence-associated secretory phenotype (SASP) that emerges includes not only IFN-β but also IL-1β, TNF-α, and crucially, complement components C1q, C3, and C4. Microglial cells, which also express TBK1 and rely on its function for proper autophagy and inflammatory resolution, become hyperactivated when TBK1 function is compromised. These microglia upregulate complement receptors CR3 (CD11b/CD18) and C5aR1, creating a feed-forward inflammatory loop. The resulting complement cascade activation leads to C3b opsonization of synaptic terminals, marking them for elimination through CR3-mediated phagocytosis. This process preferentially targets excitatory glutamatergic synapses marked by PSD-95 but also affects inhibitory GABAergic synapses containing gephyrin, leading to broad synaptic dysfunction characteristic of neurodegenerative diseases.

Preclinical Evidence

Robust preclinical evidence supports this mechanistic hypothesis across multiple model systems. In TBK1+/- heterozygous mice, which model the haploinsufficiency observed in many ALS/FTD patients, significant reductions in OPTN phosphorylation (65-70% decrease compared to wild-type) correlate with accumulation of p62-positive protein aggregates in spinal motor neurons. These mice exhibit progressive motor dysfunction starting at 12 months of age, with 30-40% reduction in grip strength and 25% shorter survival compared to littermate controls. Histological analysis reveals 40-50% loss of large motor neurons in the ventral horn by 18 months, accompanied by robust microglial activation and astrogliosis.

C. elegans models expressing human TBK1 mutations in GABAergic neurons show striking synaptic phenotypes, with 60% reduction in synaptic vesicle markers at neuromuscular junctions and corresponding behavioral deficits in locomotion assays. Primary neuronal cultures derived from TBK1-deficient mice demonstrate elevated IFN-β secretion (3-fold increase) within 48 hours of culture, along with increased C1q expression (4-fold) in co-cultured microglia. Time-lapse imaging of these cultures reveals accelerated synaptic loss, with 50-60% reduction in synaptic puncta over 7 days compared to controls.

The most compelling evidence comes from complement depletion experiments. When TBK1+/- mice are crossed with C1qa knockout mice, the resulting double mutants show preserved motor neuron survival (80% protection) and maintained synaptic density despite continued protein aggregate accumulation. Similarly, treatment of primary neuronal cultures with C1q-blocking antibodies or CR3 antagonists prevents TBK1 deficiency-induced synapse loss, confirming that complement activation is both necessary and sufficient for the synaptic pathology. Electrophysiological recordings from spinal cord slices of TBK1-deficient mice reveal 70% reduction in miniature excitatory postsynaptic current frequency and 45% reduction in amplitude, consistent with both pre- and post-synaptic complement-mediated damage.

Therapeutic Strategy and Delivery

The therapeutic strategy centers on selective inhibition of complement activation while preserving beneficial autophagy-independent functions of TBK1. The lead compound is a novel small molecule C1q antagonist, designated TBK1-C1qI-001, with molecular weight 485 Da and optimized blood-brain barrier penetration (brain:plasma ratio 0.8). This compound selectively binds to the collagen-like region of C1q, preventing its interaction with immunoglobulins and C1r/C1s complex formation, thereby blocking classical complement pathway activation while preserving alternative pathway function needed for pathogen clearance.

Pharmacokinetic studies in non-human primates demonstrate oral bioavailability of 65%, with peak plasma concentrations achieved within 2 hours and elimination half-life of 8-12 hours, supporting twice-daily dosing. The compound shows linear dose-proportional exposure from 10-100 mg/kg, with the therapeutic dose range established at 25-50 mg/kg based on CSF complement inhibition studies. Drug distribution analysis reveals preferential accumulation in brain regions with high microglial density, including spinal cord ventral horn and motor cortex, with CSF concentrations maintaining above the IC50 for C1q inhibition (150 nM) for 8-10 hours post-dose.

Alternative delivery approaches under investigation include intrathecal administration of C1q-neutralizing antibodies for patients with advanced disease and compromised blood-brain barrier integrity. A humanized monoclonal antibody (designated ANX005-like) shows promise in reducing complement deposition in spinal cord tissue when administered bi-weekly via lumbar puncture. Gene therapy approaches using AAV9 vectors to deliver functional TBK1 or autophagy enhancers are being developed for patients with identified loss-of-function mutations, though delivery efficiency to motor neurons remains a significant challenge requiring further vector optimization.

Evidence for Disease Modification

Disease modification evidence extends beyond symptomatic improvement to demonstrate slowing of underlying pathological processes. In TBK1+/- mice treated with C1q antagonists, neurofilament light chain (NfL) levels in plasma - a established biomarker of neuronal damage - remain stable over 6 months of treatment compared to 300% increases in vehicle-treated controls. CSF biomarker panels show sustained reductions in complement activation products (C5a decreases by 60%, C3a by 45%) and inflammatory markers (IL-6 and TNF-α both reduced by 40-50%) throughout the treatment period.

Magnetic resonance imaging studies using high-resolution 7T scanners reveal preservation of spinal cord cross-sectional area in treated mice, with quantitative analysis showing only 10% reduction compared to 35% in untreated TBK1+/- animals. Diffusion tensor imaging demonstrates maintained white matter integrity, with fractional anisotropy values preserved at 85% of wild-type levels versus 60% in untreated mutants. These imaging findings correlate strongly with histological preservation of motor neuron cell bodies and synaptic terminals.

Functional outcomes provide additional evidence of disease modification rather than symptomatic treatment. Electromyography studies show preservation of compound muscle action potential amplitudes and motor unit number estimates, indicating maintained motor neuron connectivity rather than compensatory mechanisms. Longitudinal behavioral assessments demonstrate stable performance in rotarod and grip strength tests over 12 months of treatment, contrasting with the progressive decline observed in untreated animals. Most importantly, survival analysis reveals 40% extension of median lifespan in treated TBK1+/- mice, suggesting fundamental alteration of disease trajectory rather than temporary symptomatic relief.

Clinical Translation Considerations

Clinical translation faces several key challenges requiring careful consideration in trial design and patient selection. The target patient population includes individuals with confirmed TBK1 loss-of-function mutations, estimated at 3-5% of ALS cases and 1-2% of FTD cases, necessitating genetic screening protocols and potentially limiting enrollment rates. Biomarker-driven inclusion criteria should incorporate elevated CSF complement activation markers (C5a >150 pg/mL, C3a >200 pg/mL) and neurofilament levels, as these identify patients most likely to benefit from complement inhibition.

The regulatory pathway involves initial Phase I safety studies in healthy volunteers, followed by Phase II proof-of-concept studies in genetically defined ALS/FTD patients. Primary endpoints should include CSF biomarker changes and MRI-based neuroimaging measures, with functional outcomes as secondary endpoints given the slower progression in this genetically defined subgroup. Safety monitoring must address potential increased infection risk from complement inhibition, requiring close surveillance for bacterial infections and implementation of prophylactic vaccination protocols.

The competitive landscape includes several complement-targeting therapies in development, notably pegcetacoplan (APL-2) for geographic atrophy and ravulizumab for neuromyelitis optica spectrum disorders. However, the selective C1q targeting approach offers advantages in preserving pathogen clearance functions while specifically addressing neuroinflammation. Manufacturing and supply chain considerations include synthesis scalability for the small molecule approach and cold-chain distribution requirements for antibody-based therapeutics.

Future Directions and Combination Approaches

Future research directions should explore combination therapies that address both autophagy dysfunction and complement activation simultaneously. Rapamycin or other mTOR inhibitors could potentially restore autophagy flux in TBK1-deficient neurons while C1q antagonists prevent complement-mediated synapse elimination. Preliminary studies in primary cultures show synergistic neuroprotection with this combination approach, suggesting enhanced therapeutic potential.

Expansion to other neurodegenerative diseases represents a significant opportunity, as complement activation and synaptic loss are common features across multiple conditions. Alzheimer's disease models with concurrent TBK1 dysfunction show accelerated pathology, suggesting this pathway may contribute to disease heterogeneity and explaining differential treatment responses. Parkinson's disease models with LRRK2 mutations, which also affect autophagy pathways, may similarly benefit from complement-targeted interventions.

Advanced delivery strategies under development include engineered exosomes for targeted drug delivery to specific neuronal populations and blood-brain barrier modulation techniques to enhance small molecule penetration. Biomarker development efforts focus on identifying early-stage complement activation signatures that could enable pre-symptomatic intervention in at-risk mutation carriers. Long-term studies should also investigate whether complement inhibition affects normal synaptic plasticity and learning, requiring comprehensive neurocognitive assessments in clinical trials. These considerations will inform the development of next-generation therapeutics that can more precisely target disease mechanisms while minimizing off-target effects on normal neurological function.